Project Grant R01AI201766
- The National Institute of Allergy and Infectious Diseases awarded Texas Biomedical Research Institute $927,025 on May 11, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to evaluate IL-21-IGFC therapy for enhancing pulmonary immune reconstitution and limiting viral persistence in co-infected macaques. The research addresses incomplete immune reconstitution in individuals co-infected with HIV and tuberculosis despite antiretroviral therapy, using an established...
- The National Institute of Allergy and Infectious Diseases awarded The University of Texas Southwestern Medical Center $281,500 on August 3, 2026, to investigate human neutralizing autoantibodies to interferon-gamma underlying mycobacterial diseases under the Allergy and Infectious Diseases Research program (CFDA 93.855). The research addresses the hypothesis that tuberculosis in some patients is caused by interferon-gamma autoantibodies with lower titer and/or lower affinity than those...
- The National Institute of Allergy and Infectious Diseases awarded $297,000 to Texas Biomedical Research Institute on September 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to fund research on targeting super-enhancers to regulate HIV transcription and latency. The project, identified as R21AI203697, will define molecular mechanisms by which super-enhancer-associated long non-coding RNAs (SE-lncRNAs) regulate HIV transcription and maintain viral latency in...
- The National Institute of Allergy and Infectious Diseases awarded Baylor College of Medicine $752,172 on September 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to conduct a mechanistic study of an RNA translocase via integrative multi-resolution approach. The research investigates how mycobacteria persist in the host by examining a conserved bifunctional RNA helicase and nuclease enzyme found across mycobacterium species. The enzyme is thought to promote...
- Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded The University of Texas Southwestern Medical Center a $3.28 million Project Grant on August 21, 2025, under the Allergy and Infectious Diseases Research program (CFDA 93.855). The four-year research initiative, scheduled for completion on July 31, 2029, focuses on elucidating the mechanisms by which host ubiquitin ligases and deubiquitinases regulate immune responses against Mycobacterium tuberculosis...
- The National Institute of Allergy and Infectious Diseases awarded $596,318 to The University of Texas Southwestern Medical Center on February 10, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to define virulence factor functions in Salmonella enterica using minimal pathogen genomes. The research characterizes how a small network of SPI-2 type III secretion system effector proteins coordinate membrane scission of the Salmonella-containing vacuole (SCV) and...
- Federal Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded The Methodist Hospital Research Institute a $2.71 million Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) on August 12, 2025, for research extending through May 31, 2029. This award supports the development and characterization of a novel generation of self-adjuvanted messenger RNA (mRNA) vaccines targeting Mycobacterium tuberculosis (MTB), the causative...
- The National Institute of Allergy and Infectious Diseases awarded Trustees of Tufts College (doing business as Tufts University School of Medicine) $315,700 on January 29, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855). The award funds research elucidating spatio-temporal innate immune cell modulation of Mycobacterium tuberculosis stress response and replication heterogeneity. The project investigates how spatial organization of tuberculosis lesions in the lung...
- The National Institute of Allergy and Infectious Diseases awarded The University of Texas Southwestern Medical Center $249,000 on July 20, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855). The award funds research to develop tools for marginal zone-specific gene expression manipulation in B cells. The project investigates how mature B cell subsets—follicular, marginal zone, and B-1 cells—contribute to protective immune responses in infection and pathogenic responses...
- Federal Project Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded The University of Texas Southwestern Medical Center a $1.14 million Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) on September 11, 2025, for a five-year research initiative extending through August 31, 2030. This award funds investigator-initiated research investigating the mechanisms of Mycobacterium tuberculosis (MTB) transmission through...
The National Institute of Allergy and Infectious Diseases (NIAID), a component of the Department of Health and Human Services National Institutes of Health, awarded $824,278 to Texas Biomedical Research Institute on August 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) for Project Grant R01AI201766. The award funds comparative investigation of bacterial antigen presentation mechanisms in Mycobacterium tuberculosis and Francisella tularensis infections to identify metabolite antigens capable of inducing protective mucosal-associated invariant T (MAIT) cell responses. MAIT cells, an innate-like T cell population abundant at mucosal surfaces, recognize non-peptidic metabolite antigens presented by MR1 (major histocompatibility complex-related protein 1) and mount rapid immune responses against bacterial infections. The research seeks to resolve which metabolite antigens activate MAIT cells protectively and how different bacterial infection routes—endosomal for M.tb and cytosolic for F. tularensis—mediate antigen loading for differential MAIT cell protection. Current knowledge gaps prevent therapeutic design of effective antigenic metabolites delivered via appropriate pathways for MAIT cell-directed protection against these bacterial pathogens. Texas Biomedical Research Institute, doing business as Southwest Foundation for Biomedical Research, is a non-profit research organization headquartered in San Antonio, Texas and hosts the Southwest National Primate Research Center. The institute operates as a prime recipient on federal infectious disease research and vaccine development grants, with substantial experience in non-human primate models and laboratory studies. Performance occurs in San Antonio, Texas 78227, with a period of performance from August 1, 2026, through July 31, 2031.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $824.3k | 8/4/26 |